Please assess the completion status of the following clinical trial:

Trial Title: Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least one measurable lesion (the length of spiral CT scan (\> 10mm) meets the requirements of RESCIST 1.1) is found in patients with HCC confirmed by histopathology or cytology or who meet the clinical diagnostic criteria.~* ≥ 18 and ≤ 75 years of age~* ECOG performance status of 0-1~* No prior treatment for advanced disease (adjuvant therapy allowed)~* Life expectancy of at least 3 months~* The main organs are functioning normally.~* Neutrophils count =/\> 1.5 x 109/L, platelets count =/\> 100 x 109/L, HGB =/\> 90 g/L~* total bilirubin =/\< 1.5 x UNL • SGOT and SGPT =/\< 2.5 x UNL (=/\< 5 x UNL in patients with liver metastases)~* Creatinine =/\< 1.5 x UNL~* Patients who are molecularly diagnosed as having RAS and BRAF wild-type mCRC are Histologically/cytologically confirmed as advanced, colorectal cancer.~* Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.~Exclusion Criteria:~* Pregnant or lactating women.~* Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments.~* Patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure \> 150 mmHg, diastolic blood pressure \> 100 mmHg), patients with myocardial infarction, arrhythmias with poor control (including QTC interval \> 450 ms) and cardiac insufficiency of grade II according to NYHA standard.~* with bleeding tendency or undergoing thrombolysis or anticoagulation therapy.~* serious uncontrolled intercurrence infection.~* Proteinuria ≥ 2+ (1.0g/24hr).~* Have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness.~* Within 6 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.~* Have a history of mental illness or psychotropic drug abuse.~* Patients with a history of immunodeficiency(or autoimmue disease), or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and hematopoietic stem cell transplantation.~* Patients who are allergic to components of Capecitabine preparations, Oxaliplatin injection and anlotinib preparations.~* According to the researchers' judgment, there are serious concomitant diseases that endanger patient safety or prevent patients from completing the study.~* Patients who have received prior systemic chemotherapy, targeted therapy, immunity therapy or any medication within 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Patients in the study group will receive the following treatment:~21 days as a treatment cycle, Anlotinib 12 mg/day, Orally(D1-D14); Capecitabine 850 mg/m2,Orally(D1-D14), Bid; Oxaliplatin 130 mg/m2, iv(D1).~If anlotinib is not tolerated(except Hand-foot skin reaction), the dose can be reduced to 10mg or 8mg ,until un-tolerable toxicity again. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).